



Highly efficient inoculum propagation in perfusion culture using WAVE Bioreactor systems

Intellectual Property Notice: The Biopharma business of GE Healthcare was acquired by Danaher on 31 March 2020 and now operates under the Cytiva™ brand. Certain collateral materials (such as application notes, scientific posters, and white papers) were created prior to the Danaher acquisition and contain various GE owned trademarks and font designs. In order to maintain the familiarity of those materials for long-serving customers and to preserve the integrity of those scientific documents, those GE owned trademarks and font designs remain in place, it being specifically acknowledged by Danaher and the Cytiva business that GE owns such GE trademarks and font designs.

cytiva.com

GE and the GE Monogram are trademarks of General Electric Company.
Other trademarks listed as being owned by General Electric Company contained in materials that pre-date the Danaher acquisition and relate to products within Cytiva's portfolio are now trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.
Cytiva and the Drop logo are trademarks of Global Life Sciences IP Holdco LLC or an affiliate.
All other third-party trademarks are the property of their respective owners.
© 2020 Cytiva
All goods and services are sold subject to the terms and conditions of sale of the supplying company operating within the Cytiva business. A copy of those terms and conditions is available on request. Contact your local Cytiva representative for the most current information.
For local office contact information, visit cytiva.com/contact

CY13394-13May20-AN

Highly efficient inoculum propagation in perfusion culture using WAVE Bioreactor™ systems

A perfusion-based process was developed to drastically increase the split ratio during the scale-up of CHO-S cell cultures. Fed-batch cultures were inoculated with cells propagated in either batch or perfusion cultures. All cultures were grown in disposable Cellbag™ bioreactors using the WAVE Bioreactor system. Cell concentrations of 4.8×10^7 cells/mL were achieved in perfusion culture, whereas the final cell concentration in batch culture was 5.1×10^6 cells/mL. The higher cell concentration allowed to increase the split ratio more than 6-fold to about 1:30 for inoculum propagated in perfusion culture. The method described here could reduce the number of required expansion steps and eliminate one or two bioreactors in the seed train. Disposable bioreactors with only a few liters working volume have the potential to directly inoculate volumes of up to 1000 liters. Alternatively high biomass concentrations accumulated in perfusion culture can be used to seed production bioreactors at increased cell concentrations. This would allow to shorten process time in these bioreactors, which often is the bottleneck in plant throughput.

Introduction

Inoculum propagation in animal cell culture is typically done in a series of batch cultures with increasing cultivation volume until a sufficient cell number is obtained for seeding of the final production reactor. The maximum cell concentration achieved in these pre-cultures limits the split ratio and requires the use of several bioreactors in the seed train. Typically, sequential expansion steps with split ratios of 1:5 to 1:10 are used. In perfusion culture substantially




Fig 1. WAVE Bioreactor in perfusion set-up.

higher cell concentrations are reached. Therefore, higher dilutions are possible and the number of expansion steps can be reduced.

Disposable bioreactors are increasingly used for cell cultivation because they improve process flexibility, shorten turnover times, and eliminate the requirement for cleaning and sterilization. Numerous animal cell lines such as CHO, HEK, NS0, S2 and SF9 have been cultivated successfully in WAVE Bioreactor systems, demonstrating the flexibility of this device (1–5).

In this study cells were expanded in single-use reactors using the WAVE Bioreactor system equipped with an automated control for perfusion culture. A schematic drawing of the reactor is shown in Figure 1. The cells are grown in a pre-sterilized, inflated cultivation chamber, a Cellbag bioreactor. The culture is mixed by rocking the bag attached to the rocker tray. Heating occurs via a heater pad located below the tray and gas supply is provided via the headspace that can be filled with a mixture of ambient air and CO₂, to support high cell concentration also additional



O₂ can be blended in. The reactor is equipped with probes for measurement of dissolved oxygen (DO) and pH. The parameters are controlled by a WAVEPOD™ II process control unit. In perfusion mode the cells are retained inside the reactor by an integrated filter with a nominal pore size of 7 µm that floats on the culture surface. Agitation causes lateral movement of the filter, which delays cell attachment and prolongs filter lifetime. The perfusion rate is controlled via an integrated load cell that ensures periodic addition and removal of equal amounts of feed and harvest. The setup for perfusion culture is shown in Figure 1. Cell retention via the integrated filter eliminates the need for an external recirculation loop and cultivations can be performed in preconfigured Cellbag bioreactors, available for working volumes from 1 to 25 liters.

Materials and methods

Cell line and cultivation medium

CHO-S cells (Invitrogen) were used in this study. The cells were grown in serum-free medium (T13, Shanghai Hankang Biotech Co.). For fed-batch cultivations a nutrient concentrate (T13-F) from the same manufacturer was used.

Bioreactor cultivations

All cultivations were performed in WAVE Bioreactor 20/50 system EHT. For batch and fed-batch cultivations Cellbag 10L at a working volume of 4 liters were used. Perfusion culture was performed in a Cellbag 2L at a working volume of 1 liter. Culture conditions were controlled by a WAVEPOD II controller. Set points were 7.10 for pH and 40% air saturation for DO. Oxygen was provided via headspace aeration using ambient air at a flow rate of 0.2 liters per minute (Lpm). Agitation settings of 25 rpm and 6° were used for all cultures.

Cultures were monitored by daily cell count and viability determination in a hemocytometer using the trypan blue exclusion method. Additionally, glucose and lactate concentrations were measured using an enzymatic bioanalyzer (SBA-40C, Shandong Academy of Sciences, China). Feed additions and perfusion rate were adjusted daily to keep the residual glucose concentration higher than 0.5 g/L. Inoculum from batch and perfusion cultures was removed at the end of the exponential growth phase while they were still growing at maximum rate. Both cultures were continued afterwards to investigate cell growth and maximum cell concentrations. In perfusion culture the medium exchange was 1.5 culture volumes per day when the inoculum was removed for the subsequent fed-batch. During the following two days, until termination of the culture, perfusion was increased to a maximum of 3.7 culture volumes per day.

The fed-batch cultures, inoculated from batch and perfusion culture, were terminated at 60% viability.

Results and Discussion

Inoculum propagation

CHO-S cells were grown in either batch or perfusion culture to generate inocula for subsequent fed-batch cultivations. During the initial phase cell growth in both cultures was similar (Fig 2). However, despite high cell viability, the growth rate in the batch culture decreased from $0.8 \times d^{-1}$ during the first two days to about $0.3 \times d^{-1}$ between days 2 and 6. Medium exchange in the perfusion culture was started on day 2. The nutrient supply supported an average growth rate of $0.8 \times d^{-1}$ until day 5, as shown by the constant slope of the growth curve in Figure 2. Inoculum was removed from each seed culture while the cells were still growing at their maximum rate and while viability was higher than 95%.




Fig 2. CHO-S cells were grown in batch and perfusion culture. Seed material for a subsequent fed-batch was removed at the indicated time points. CC = cell concentration; FB = fed-batch.

Fed-batch cultures

The higher cell concentration achieved in perfusion culture was used to seed the subsequent fed-batch at an increased split ratio of 1:30 compared with 1:5 used for the inoculum from the batch culture. Cell growth in the two subsequent fed-batch cultures is shown in Figure 3. The cultures inoculated from either batch or perfusion culture had comparable growth at an average rate of $0.6 \times d^{-1}$ until day 5. No lag phase was observed post inoculation. The maximum cell concentrations were 1.73×10^7 cells/mL on day 6 for the fed-batch inoculated from perfusion culture and 1.42×10^7 cells/mL reached on day 8 for the fed-batch inoculated from batch culture. The difference can be explained by the higher inoculum concentration in the process seeded from the perfusion culture.

A comparison of individual culture parameters is presented in Table 1. The higher split ratio in perfusion culture saves at least one step in the inoculum propagation as compared to batch mode for which two subsequent cultures with a split ratio of 1:5 would be required to obtain a similar ratio. Even higher split ratios can be achieved when a slight reduction




Fig 3. Comparison of CHO-S fed-batch cultures inoculated from either a batch or a perfusion culture.

of the growth rate from 0.8 to $0.6 \times d^{-1}$ is accepted. Although the cells were no longer in exponential growth phase, the viability still was 96% at a cell concentration of 4.06×10^7 cells/mL on day 6 (Fig 2). Seeding at a cell concentration of 4×10^5 cells/mL would allow a split ratio of 1:100. Figure 3 shows that the culture seeded at an 80% higher inoculum concentration reached the maximum cell concentration about 2 days earlier. Additionally also the viable cell integral was increased by about 20% (data not shown). Assuming constant product formation during cell growth, this would allow to also reach the same amount of product two days earlier and thus shorten process time in the main bioreactor.

Table 1. Comparison of fed-batch cultures. Inoculum propagated in either batch or perfusion culture

	Fed-batch (seeded from batch)	Fed-batch (seeded from perfusion)
Cell conc. at seed removal (cells/mL)	2.2×10^6	2.3×10^7
Split ratio	1:5	1:30
Starting cell concentration (cells/mL)	4.1×10^5	7.4×10^5
Culture time (d)	14	14
Max. cell conc. (cells/mL)	1.4×10^7	1.7×10^7
μ av. until max. cell conc. (d^{-1})	0.44	0.52

Conclusions

Based on the results from this study, propagation of inoculum in a perfusion culture can be used to achieve an at least 5 to 10-fold higher split ratio compared with traditional cell expansion in batch cultures. This in turn offers the possibility to reduce the number of steps in a seed train and consequently also the investment cost for bioreactors. Single-use bioreactors reduce turnover times and improve process flexibility. The maximum culture volume of the WAVE Bioreactor 20/50 system is 25 liters.

Run in perfusion mode, the reactor can directly provide inoculum for working volumes up to 1000 liters. An example of seed-train expansion in batch versus perfusion culture is shown in Figure 4. Furthermore perfusion cultures could also be used to seed production reactors at higher cell concentrations, thereby shortening process time in these reactors and improving facility throughput.




Fig 4. WAVE Bioreactor systems with Cellbag bioreactors substantially decreases seed-train expansion steps. This figure shows the potential to directly inoculate cultures up to 1000 L.

References

1. Singh, V. Disposable bioreactor for cell culture using wave-induced agitation. *Cytotechnology* **30**, 149–158 (1999).
2. Namdev, P. K. and Lio, P. Assessing a disposable bioreactor for attachment dependent cell cultures. *BioPharm Int.* **13**, 44–50 (2000).
3. Tang Y. J. *et al.* Perfusion culture of hybridoma cells for hyperproduction of IgG(2a) monoclonal antibody in a wave bioreactor-perfusion culture system. *Biotechnol. pro.* **23**, 255–264 (2007).
4. Birch, J. R. and Racher, A. J. Antibody production. *Adv. Drug Deliv. Rev.* **58**, 671–685 (2006).
5. Chartrain, M. and Chu, L. Development and production of commercial therapeutic monoclonal antibodies in mammalian cell expression systems: an overview of the current upstream technologies. *Curr. Pharm. Biotechnol.* **9**, 447–467 (2008).

Ordering information

Product	Code number
Cellbag	
Cellbag 2 L (pHOPT and perfusion version)	29-0123-55
Cellbag 10 L (pHOPT and perfusion version)	29-0123-60
Cellbag 20 L (pHOPT and perfusion version)	29-0124-60
Cellbag 2 L (pHOPT and screwcap version)	29-0123-53
Cellbag 10 L (pHOPT and screwcap version)	29-0123-57
Cellbag 20 L (pHOPT and screwcap version)	29-0124-55
Cellbag 2 L (DOOPT II, pHOPT and perfusion version)	29-0153-08
Cellbag 10 L (DOOPT II, pHOPT and perfusion version)	29-0153-12
Cellbag 20 L (DOOPT II, pHOPT and perfusion version)	29-0153-15
Cellbag 2 L (DOOPT II, pHOPT and screwcap version)	29-0153-07
Cellbag 10 L (DOOPT II, pHOPT and screwcap version)	29-0153-09
Cellbag 20 L (DOOPT II, pHOPT and screwcap version)	29-0153-13
WAVE Bioreactor system	
BASE20/50EHT-L 110-120V	28-9413-43
BASE20/50EHT-L 220-240V	28-9413-44
WAVEPOD II Integrated Controller	
WAVEPOD II CO2 pHOPT	28-9847-41
WAVEPOD II O2 DOOPT II	29-0016-34
WAVEPOD II CO2 O2 pHOPT DOOPT II	29-0016-32

For local office contact information, visit
www.gelifesciences.com/contact

www.gelifesciences.com/readytoprocess

GE Healthcare Bio-Sciences AB
Björkgatan 30
751 84 Uppsala
Sweden



imagination at work

GE, imagination at work and GE monogram are trademarks of General Electric Company.

Cellbag, ReadyToProcess, WAVE Bioreactor, and WAVEPOD are trademarks of GE Healthcare companies.

© 2012 General Electric Company — All rights reserved.
First published Apr. 2012

All goods and services are sold subject to the terms and conditions of sale of the company within GE Healthcare which supplies them. A copy of these terms and conditions is available on request. Contact your local GE Healthcare representative for the most current information.

GE Healthcare UK Limited
Amersham Place
Little Chalfont
Buckinghamshire, HP7 9NA
UK

GE Healthcare Europe, GmbH
Munzinger Strasse 5
D-79111 Freiburg
Germany

GE Healthcare Bio-Sciences Corp.
800 Centennial Avenue, P.O. Box 1327
Piscataway, NJ 08855-1327
USA

GE Healthcare Japan Corporation
Sanken Bldg., 3-25-1, Hyakunincho
Shinjuku-ku, Tokyo 169-0073
Japan